New test could make diagnosis of thirst disorders easier for patients

NCT ID NCT07569861

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares a new diagnostic test using mannitol infusion to the standard hypertonic saline test for diagnosing the cause of polyuria-polydipsia syndrome (excessive urination and thirst). Researchers will enroll 144 adults to see if the mannitol test is as accurate and more comfortable for patients. The goal is to find a simpler way to diagnose conditions like arginine vasopressin deficiency and primary polydipsia.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Mannitol and hypertonic saline (diagnostic agents)
What this could lead to
If successful, this could provide a simpler, more comfortable diagnostic test for people with excessive thirst and urination, replacing the current standard test.
What could go wrong
This is a relatively small, early-phase diagnostic study. The mannitol test may not be as accurate as the standard test, and results may not apply to all patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARGININE VASOPRESSIN DEFICIENCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes insipidus Diabetes Insipidus, Neurogenic neurohypophyseal diabetes insipidus Polydipsia, Psychogenic primary polydipsia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University Hospital Basel

    RECRUITING

    Basel, 4031, Switzerland

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.